



2020

Comparison Of The Effects Of Ticagrelor And Clopidogrel On Heart Rate Variability And Heart Rate Turbulence In Patients With Percutaneous Coronary Interventions

Follow this and additional works at: <https://www.j-saudi-heart.com/jsha>



Part of the [Cardiology Commons](#)



This work is licensed under a [Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License](#).

Recommended Citation

Yagcioglu, Pinar; Ari, Selma; Ari, Hasan; and Melek, Mehmet (2020) "Comparison Of The Effects Of Ticagrelor And Clopidogrel On Heart Rate Variability And Heart Rate Turbulence In Patients With Percutaneous Coronary Interventions," *Journal of the Saudi Heart Association*: Vol. 32 : Iss. 2 , Article 7. Available at: <https://doi.org/10.37616/2212-5043.1048>

This Original Article is brought to you for free and open access by Journal of the Saudi Heart Association. It has been accepted for inclusion in Journal of the Saudi Heart Association by an authorized editor of Journal of the Saudi Heart Association.

Comparison of the Effects of Ticagrelor and Clopidogrel on Heart Rate Variability and Heart Rate Turbulence in Patients with Percutaneous Coronary Interventions

Pinar Yagcioglu, Selma Ari, Hasan Ari*, Mehmet Melek

Bursa Postgraduate Hospital, Departments of Cardiology, Bursa, Turkey

Abstract

Introduction: Clopidogrel and ticagrelor are commonly used, antiplatelet agents. Ticagrelor has an effect of enhancing the plasma level of adenosine that may alter the autonomic function. The aim of this study is to compare the effects of ticagrelor and clopidogrel on heart rate variability (HRV) and heart rate turbulence (HRT).

Methods: Thirty subjects who performed percutaneous coronary intervention (PCI) were included in the randomized, crossover study. These patients were divided into two groups. Clopidogrel or ticagrelor was administered in two different testing sessions (1-month treatment for each session). In group 1, clopidogrel and ticagrelor treatment were used while in group 2, ticagrelor and clopidogrel treatment were used respectively. Three times rhythm Holter recording (baseline, 1st and 2nd month) was performed. The HRV (time domain and frequency domain) and HRT (turbulence onset (TO) and turbulence slope (TS)) parameters were analyzed from the Holter recordings.

Results: According to baseline Holter recording, pNN50 (5.82 ± 5.83 vs 10.56 ± 8.28 ; $p = 0.03$) and HF(nu) (6.85 ± 9.33 vs 9.53 ± 7.41 ; $p = 0.04$) parameters were higher in group 2 than in group 1, while TO (0.004 ± 0.02 vs -0.01 ± 0.02 ; $p = 0.01$) parameter was positive and higher in group 1 than in group 2. In the second month, the LF/HF ratio (4.47 ± 2.43 vs 3.18 ± 2.45 ; $p = 0.04$) was higher in group 1 than in group 2. However, when the evaluation was done within the groups themselves, there were no statistically significant differences in HRV and HRT parameters obtained before and after clopidogrel and ticagrelor administration in group 1 and group 2.

Conclusion: Ticagrelor and clopidogrel treatments did not have a significant effect on HRV and HRT parameters.

Keywords: Ticagrelor, Clopidogrel, Heart rate variability, Heart rate turbulence

1. Introduction

In patients undergoing percutaneous coronary intervention (PCI), the use of antiagregan is a standard treatment. The most commonly used antiplatelet agents today are aspirin, clopidogrel, ticagrelor and prasugrel [1–4]. Unlike other agents, ticagrelor has an effect of enhancing the plasma level of adenosine by inhibiting adenosine reuptake [5,6]. This effect is considered to be the

mechanism responsible for the side effects of ticagrelor such as dyspnea and ventricular pause [7]. On the other hand Ortega-Paz et al. found that the dispnea is related with the ticagrelor plasma concentration [8]. In vivo study, Gourine et al. showed that adenosine triphosphate dependent mechanism activated chemoreceptor neurons and increases in breathing [9]. Furthermore, increase the circulating levels of adenosine

Received 8 February 2020; revised 16 April 2020; accepted 17 April 2020.
Available online 12 May 2020

* Corresponding author. Kardiyoloji Kliniği, Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Yıldırım, Bursa, Turkey. Fax: +90 224 3605055.
E-mail addresses: pnrgh@yahoo.com (P. Yagcioglu), selmakulekci@yahoo.com.tr (S. Ari), hasanari03@yahoo.com (H. Ari), mehmetmelek73@gmail.com (M. Melek).



or ticagrelor may effect the cardiac othonomic function [6,8,9].

Adenosine receptors are widely found through the body and bring about very different effects, both directly and indirectly, wherever they are. It is known that adenosine has effects on the autonomic nervous system [10]. The most important factor in regulating heart rate is autonomic nervous system activity [11,12]. Heart rate variability (HRV) and heart rate turbulence (HRT) are reliable parameters used to evaluate autonomic functions in various diseases. HRV shows periodic changes in unit time over sinus velocity. With this method, spectral analysis of electrocardiographic (ECG) signals is performed, cardiac autonomic tonus can be assessed based on some specific frequency bands associated with the parasympathetic and sympathetic nervous system [13,14]. HRT is defined as physiologic changes in sinus velocity after premature ventricular extrasystole (VES) and is accepted as a sign of baroreflex sensitivity [15]. Several studies have shown that impaired HRT in cardiac disease is associated with mortality [16].

There is no previous study evaluating the efficacy of clopidogrel and ticagrelor on cardiac autonomic function. In this study, it was aimed to evaluate the effects of clopidogrel and ticagrelor on cardiac autonomic functions with HRT and HRV parameters.

2. Materials and method

2.1. Subjects and study design

Two times (at least 6 h apart) troponin negative low-risk acute coronary syndrome patients who applied to our cardiology clinic were consecutively included in the study. These patients had not ECG changes, left ventricular wall motion abnormality and ongoing chest pain. Signed informed consent form was obtained from each patient. The study group consisted of 30 patients who were diagnosed with coronary artery stenosis after coronary angiography. Patients with myocardial infarction, diabetes mellitus, atrial fibrillation, malignant tumors, active infection findings, thyroid dysfunction, cerebrovascular events, chronic obstructive pulmonary disease (COPD), left ventricular wall motion abnormality, heart valve disease, pulmonary hypertension and requiring urgent coronary intervention were excluded from the study. Prior to PCI, clopidogrel and appropriate antiatherosclerotic treatment were given according to the clinical

Abbreviations

ASDNN	Standard deviation of the average R–R interval
HF	High frequency
HRT	Heart rate turbulence
HRV	Heart rate variability
LF	Low frequency
PCI	Percutaneous coronary intervention
pNN50	Percentage of pairs of adjacent R–R intervals differing by more than 50 ms
rMSSD	Root mean square of successive R–R interval differences
SDNN	Standard deviation of the R–R interval
TO	Turbulence onset
TP	Total power
TS	Turbulence slope
VLF	Very-low-frequency

characteristics of the patient for 1 week. At the end of 1 week 24-h rhythm Holter records were taken and the patient was treated with PCI 1 day later. Cardiac enzymes, renal function tests and hemogram parameters were observed 1 day before the procedure and patients were discharged 1 day after the procedure with medical treatments according to their clinical characteristics. The patients were randomized into two groups automatically by a computer program according to their application number of our clinic.

15 patients were discharged with clopidogrel treatment, while 15 patients were discharged with ticagrelor treatment. After 1 month, 24-h rhythm Holter records of patients were taken again, after this recording, a crossover was done between groups taking clopidogrel and ticagrelor. One month later, the third 24-h rhythm Holter recordings were performed (Fig. 1).

2.2. HRV and HRT analysis

The 24-h rhythm Holter recording was performed with the Spiderview™ recorder (Ela Medical, Paris 2007). The rhythm Holter records (baseline, 1st and 2nd month) from all patients were loaded on the computer and analyzed by the Holter program (ELA Medical SYNESCOPE MultiChannel- Multiday Version 3.10). Three periods of recording were analysed separately. First, artefacts, normal and ventricular pulses were detected in the “template” tab. Then the maximum, minimum, and mean heart rates were recorded. The time-dependent HRV values were evaluated with PNN50 (percentage of pairs of adjacent R–R intervals differing by more than 50 ms), RMSSD (root mean square of




Fig.1. Study design.

successive R–R interval differences), ASDNN (standard deviation of the average R–R interval) and SDNN (standard deviation of the R–R interval) parameters. Frequency domain analysis was performed with Fast Fourier Transform. Frequency-dependent HRV parameters were detected at four different band intervals; high-frequency (HF) (0.15–0.4 Hz), Very-low-frequency (VLF) (0.0–0.04 Hz), low-frequency (LF) (0.04–0.15 Hz), total power (0.0–2.0 Hz) and LF/HF ratio. The normalized high frequency power (HF nu = $100 \times$ high frequency power/total power), normalized low frequency power (LF nu = $100 \times$ low frequency power/total power), very-low-frequency power (VLF nu = $100 \times$ very-low-frequency power/total power) and low frequency power/high frequency power ratio (LF/HF ratio) were calculated to give the relative changes in HRV in the frequency domain.

The HRT parameters, turbulence onset (TO) and turbulence slope (TS) were automatically calculated by the HRT program (HRT View Version 0.60–0.1 Munich, Germany) using the appropriate VES for HRT measurement from the Holter recordings. Values less than 0% for TO and values greater than 2.5 msn/RR for TS were considered normal [12].

Loss of turbulence was recognized as an increase in TO and a decrease in TS.

2.3. Statistical analysis

Statistical analysis was performed with the SPSS 22.0 software package (SPSS Inc., Chicago, IL). All numeric variables are expressed as the mean \pm SD, and categorical variables are expressed as percentages. Inter-group comparisons were made by the Mann–Whitney U test for continuous variables and categorical variables were compared by the chi-squared test or Fisher's exact test. The repeated measurements (baseline, clopidogrel, and ticagrelor treatment periods) were analyzed with the Wilcoxon signed rank test. A p-value < 0.05 was considered statistically significant.

3. Results

The study patients were divided into 2 groups according to their treatment order. Group 1 was treated with clopidogrel-clopidogrel-ticagrelor order and group 2 was treated with clopidogrel-ticagrelor-clopidogrel order. The demographic characteristics, laboratory parameters and therapies

Table 1. Baseline characteristics of two groups.

	Group 1 (n = 15)	Group 2 (n = 15)	p Value
Age (years)	60.47 ± 7.41	58.07 ± 8.24	0.40
Gender; n (%)			
Male	14 (%93.3)	12 (%80)	0.59
Female	1 (%6.7)	3 (%20)	
Smoking, n (%)			
(active and former)	6 (%40)	6 (%40)	1
Hypertension, n (%)	11 (%73.3)	6 (%40)	0.06
Heart rate (bpm)	70.36 ± 5.67	72.09 ± 5.42	0.58
SBP (mmHg)	125.60 ± 7.60	120.66 ± 11.27	0.17
DBP (mmHg)	84.37 ± 4.17	80.33 ± 8.66	0.21
Left ventricular EF (%)	64.76 ± 2.14	65.23 ± 2.63	0.39
Hemoglobin (gr/dl)	14.23 ± 1.24	13.79 ± 1.56	0.40
WBC (10 ³ /ul)	8.88 ± 1.78	8.20 ± 1.86	0.31
Platelet (10 ³ /ul)	227.66 ± 45.60	222.06 ± 48.27	0.74
BUN (mg/dl)	16.33 ± 3.19	17.73 ± 7.86	0.52
Creatinin (mg/dl)	0.87 ± 0.18	0.87 ± 0.22	0.93
Na (mmol/l)	139.33 ± 2.49	140.60 ± 2.61	0.18
K (mmol/l)	4.32 ± 0.41	4.15 ± 0.99	0.54
LDL (mg/dl)	95.77 ± 60.17	104.82 ± 61.46	0.68
HDL (mg/dl)	45.08 ± 14.06	44.38 ± 10.27	0.87
Medication, n (%)			
ASA	15 (%100)	15 (%100)	1
Beta blocker	15 (%100)	14 (%93.3)	0.99
ACEI	11 (%73.3)	9 (%60)	0.43
Statin	11 (%73.3)	14 (%93.3)	0.33
Nitrate	1 (%6.7)	1 (%6.7)	1
Diuretic	7 (%46.7)	4 (%26.7)	0.25

SBP: Systolic blood pressure, DBP: Diastolic blood pressure, EF: Ejection fraction, ACEI: Angiotensin converting enzyme inhibitor.

were similar in both groups (Table 1). We prescribe metoprolol for all patients and the two groups beta blocker dose was similar during the Holter recording periods (group 1: 81.6 ± 33.3 vs group 2: 89.2 ± 32.0; p = 0.53). According to the initial Holter analyzes of the study groups, there was a significant difference between the groups in HF (nu), pNN50 and TO parameters (Table 2). Parameters of HF (nu) and pNN50 in group 2 were significantly higher than in group 1 (Table 2). TO parameter of group 1 was positive and significantly higher than group 2 (Table 2). There was no significant difference between the two groups in terms of HRV and HRT parameters after one month of clopidogrel and ticagrelor treatment (Table 2). The HRT parameters were similar in both groups, however, there was a difference in the LF/HF ratio in the rhythm Holter recordings after 1 month of cross-over treatment of clopidogrel and ticagrelor (Table 2). No statistically significant differences were found in HRV and HRT parameters when examining the baseline, 1st and 2nd month Holter records of group 1 patients (Table 3). According to the three rhythm Holter record periods, in group 1 only the R–R period of the 1st month was shorter than R–R period of the baseline (Table 3). According to the three rhythm Holter

record periods, in group 2 HRT and HRV parameters were similar in the three record periods (Table 4). We performed an HRV and HRT analysis for our 30 study patients in different treatment phase. All HRV and HRT parameters were similar for three treatment phase (Table 5).

Holter recordings showed no > 2 s pause, bradycardia, sustained or nonsustained tachycardia in both groups. Despite the shortness of breath during the early period of ticagrelor treatment in two patients, these complaints disappeared in following the treatment. There was no serious side effect that causes the cessation of treatment associated with respiratory functions in the study patients.

4. Discussion

In our study, the effects of clopidogrel and ticagrelor treatment on HRV and HRT were evaluated in patients with coronary artery disease treated with PCI. Both ticagrelor and clopidogrel treatments were tested in the same patient group with the cross over method. Ticagrelor and clopidogrel treatments did not have a significant effect on HRV and HRT parameters. This is the first study in the literature to evaluate the effects of ticagrelor and clopidogrel on HRT and HRV.

Ticagrelor may cause an increase in plasma concentration of adenosine by blocking intracellular reuptake of adenosine in erythrocytes, particularly through the non-sodium-dependent ENT-1 receptor [17]. In addition, the metabolites of ticagrelor (AR-C 124910, AR-C 133913 XX) inhibit ENT-1 weakly. No such effect was found in other P2Y₁₂ inhibitor antiplatelet agents [17,18]. Adenosine shows biological effects via 4 piece G proteins. A1 and A3 act on the G_i protein receptor, A2A and A2B act on the G_s protein receptor [19,20].

However Ortega-Paz et al. showed that the dyspnea is related with the ticagrelor plasma concentration and dyspnea is independent of plasma adenosine level [8]. On the other hand they did not evaluate the tissue adenosine levels and tissue sensitivity to adenosine. Higher ticagrelor concentration act these mechanism. Elevated ticagrelor may had direct pürinerjik effect to central nervous system [9]. Central nervous system could activated with chemoreceptor neurons via adenosine triphosphate [9]. This mechanism may be associated with respiratory changes.

Adenosine receptors are common and may have opposite effects relative to their localization. This is particularly striking in the effects on the autonomic nervous system [21]. For this reason, it is important to understand how adenosine acts on efferent,

Table 2. Comparison of two groups baseline, first and second month HRV and HRT parameters.

Treatment	Group 1	Group 2	p Value	Group 1	Group 2	P Value	Group 1	Group 2	p Value
	(n = 15)	(n = 15)		(n = 15)	(n = 15)		(n = 15)	(n = 15)	
Study Period	Clonidogrel	Clonidogrel		Clonidogrel	Ticagrelor		Ticagrelor	Clonidogrel	
	Baseline Recording			First Month Recording			Second Month Recording		
Mean R–R time (ms)	890.46±80.86	899.00±119.71	0.82	838.26±69.11	880.66±119.04	0.24	872.80±55.23	896.46±150.29	0.57
HRV (frequency domain)									
TP (ms ²)	3674.73±4831.70	2738.80±1883.54	0.82	3342.06±3063.51	3070.40±2480.86	0.46	3155.66±1694.67	2991.33±2504.59	0.29
VLF (ms ²)	2838.73 ± 3278.46	2173.46 ± 1470.49	0.63	2597.93 ± 2023.48	2439 ± 1831.05	0.57	2473.73 ± 1242.95	2274.66 ± 1820.46	0.23
VLF (nu)	81.68 ± 5.27	79.76 ± 5.49	0.29	81.45 ± 6.00	80.97 ± 5.87	0.69	79.50 ± 5.26	78.03 ± 6.23	0.49
LF (ms ²)	836.00±1561.29	565.33±436.17	0.72	744.13±1066.91	630.66±674.49	0.72	681.93±492.79	716.66±719.92	0.41
LF (nu)	18.31±5.27	20.23±5.49	0.29	18.54±6.00	19.02±5.86	0.69	20.49±5.26	21.96±6.23	0.49
HF(ms ²)	631.66±2044.96	242.73±203.92	0.14	542.86±1455.76	202.53±146.16	0.56	339.93±571.48	323.06±371.92	0.61
HF (nu)	6.85±9.33	9.53±7.41	0.04	8.13±10.09	7.26±4.14	0.49	7.81±8.31	10.02±7.17	0.14
LF/HF ratio	4.53±2.51	3.33±2.26	0.11	3.79±2.11	3.50±2.69	0.48	4.47±2.43	3.18±2.45	0.04
HRV (time domain)									
SDNN (ms)	99.91±27.20	108.45±42.10	0.78	113.53±26.18	116.60±37.29	0.85	110.55±26.38	110.88±34.46	0.78
ASDNN (ms)	55.73±29.78	53.47±16.89	0.91	52.06±17.03	52.83±18.99	0.98	54.43±12.85	53.85±22.50	0.31
rMSSD(ms)	39.04±56.34	38.70±17.58	0.08	38.33±34.74	34.46±13.43	0.63	36.40±25.19	40.29±24.57	0.57
pNN50 (%)	5.82±5.83	10.56±8.28	0.03	7.18±6.27	7.61±7.17	0.93	5.74±4.94	9.07±9.68	0.49
HRTparameters									
TO (%)	0.004±0.02	-0.01±0.02	0.01	-0.001±0.02	-0.012±0.02	0.09	0.001±0.03	-0.010±0.02	0.52
TS (ms)	5.55±5.34	7.39±6.05	0.19	5.94±5.21	5.33±6.57	0.24	9.06±7.22	7.77±5.21	0.78

HRV: Heart rate variability, HRT: Heart rate turbulence, TO: Turbulence onset, TS: Turbulence slope. Statistically significant ($p < 0.05$) parameters were stated as bold.

central and afferent autonomic pathways in order to understand the total effect on the cardiovascular system. The total effect of adenosine on cardiovascular autonomic regulation, via afferent pathways (via chemoreceptors) have a sympathetic activity enhancing effect and vasoconstriction and blood pressure enhancing effect, thus increasing the tissue perfusion pressure. On the other hand, it has local vasodilator effects [22]. This creates a protective effect on ischemia.

While the LF in HRV analysis represents a complex combination of sympathetic and parasympathetic effects on cardiac autonomic function, the HF generally represent innervation of the vagal of the

heart [13,23]. The LF/HF ratio is accepted as the sympathovagal balance index [13]. The fact that baseline HF (nu) and pNN50 values in group 2 were higher than in group 1 suggests that sympathovagal balance favors the parasympathetic system in group 2. Similarly, 2 months after the treatment, the LF/HF ratio was lower in group 2 than in group 1, like that in the baseline of study, suggesting the autonomic function of group 2 in favor of the parasympathetic system. Although there was a difference between the two groups HRV parameters, according to a comparison of repeated measurements (baseline, 1st, and 2nd month), HRV parameters for each group were not different. This result indicates that the drugs used

Table 3. Comparison of the baseline, first and second month HRV and HRT parameters of group 1.

Group 1 (n:15)				P Value	P Value	P Value
Treatment	Clopidogrel	Clopidogrel	Ticagrelor	Baseline vs first month	Baseline vs Second month	First month vs Second month
Study Period	Baseline Recording	First Month Recording	Second Month Recording			
Mean R–R time (ms)	890.46 ± 80.86	838.26 ± 69.11	872.80 ± 55.23	0.03	0.33	0.06
HRV (frequency domain)						
TP (ms ²)	3674.73 ± 4831.70	3342.06 ± 3063.51	3155.66 ± 1694.67	0.95	0.88	0.65
VLF (ms ²)	2838.73 ± 3278.46	2597.93 ± 2023.48	2473.73 ± 1242.95	0.91	0.92	0.99
VLF (nu)	81.68 ± 5.27	81.45 ± 6.00	79.50 ± 5.26	0.92	0.10	0.24
LF (ms ²)	836.00 ± 1561.29	744.13 ± 1066.91	681.93 ± 492.79	0.82	0.57	0.25
LF (nu)	18.31 ± 5.27	18.54 ± 6.00	20.49 ± 5.26	0.91	0.11	0.23
HF (ms ²)	631.66 ± 2044.96	542.86 ± 1455.76	339.93 ± 571.48	0.36	0.73	0.97
HF (nu)	6.85 ± 9.33	8.13 ± 10.09	7.81 ± 8.31	0.23	0.86	0.91
LF/HF ratio	4.53 ± 2.51	3.79 ± 2.11	4.47 ± 2.43	0.08	0.57	0.12
HRV (time domain)						
SDNN (ms)	99.91 ± 27.20	113.53 ± 26.18	110.55 ± 26.38	0.08	0.11	0.65
ASDNN (ms)	55.73 ± 29.78	52.06 ± 17.03	54.43 ± 12.85	0.82	0.73	0.28
rMSSD(ms)	39.04 ± 56.34	38.33 ± 34.74	36.40 ± 25.19	0.28	0.33	0.95
pNN50 (%)	4.82 ± 5.83	7.18 ± 6.27	5.74 ± 4.94	0.17	0.28	0.82
HRT parameters						
TO (%)	0.004 ± 0.02	−0.001 ± 0.02	0.001 ± 0.03	0.58	0.42	0.77
TS (ms)	5.55 ± 5.34	5.94 ± 5.21	9.06 ± 7.22	0.86	0.17	0.19

HRV: Heart rate variability, HRT: Heart rate turbulence, TO: Turbulence onset, TS: Turbulence slope. Statistically significant (p < 0.05) parameters were stated as bold.

Table 4. Comparison of the baseline, first and second month HRV and HRT parameters of group 2.

Group 2 (n:15)				P Value	P Value	P Value
Treatment	Clopidogrel	Ticagrelor	Clopidogrel	Baseline vs First Month	Baseline vs Second Month	First Month vs Second Month
Study Period	Baseline Recording	First Month Recording	Second Month Recording			
Mean R–R time (ms)	899.00 ± 119.71	880.66 ± 119.04	896.46 ± 150.29	0.64	0.95	0.33
HRV (Frequency domain)						
TP (ms ²)	2738.80 ± 1883.54	3070.40 ± 2480.86	2991.33 ± 2504.59	0.11	1.00	0.51
VLF(ms ²)	2173.46 ± 1470.49	2439 ± 1831.05	2274.66 ± 1820.46	0.21	0.86	0.57
VLF (nu)	79.76 ± 5.49	80.97 ± 5.87	78.03 ± 6.23	0.87	0.27	0.15
LF (ms ²)	565.33 ± 436.17	630.66 ± 674.49	716.66 ± 719.92	0.19	0.57	0.65
LF (nu)	20.23 ± 5.49	19.02 ± 5.86	21.96 ± 6.23	0.86	0.28	0.14
HF(ms ²)	242.73 ± 203.92	202.53 ± 146.16	323.06 ± 371.92	0.59	0.95	0.29
HF (nu)	9.53 ± 7.41	7.26 ± 4.14	10.02 ± 7.17	0.36	0.86	0.07
LF/HF ratio	3.33 ± 2.26	3.50 ± 2.69	3.18 ± 2.45	0.60	0.95	0.49
HRV (Time domain)						
SDNN (ms)	108.45 ± 42.10	116.60 ± 37.29	110.55 ± 26.38	0.07	0.69	0.33
ASDNN (ms)	53.47 ± 16.89	52.83 ± 18.99	54.43 ± 12.85	0.73	0.69	0.95
rMSSD (ms)	38.70 ± 17.58	34.46 ± 13.43	36.40 ± 25.19	0.69	0.82	0.46
pNN50 (%)	10.56 ± 8.28	7.61 ± 7.17	5.74 ± 4.94	0.17	0.28	0.62
HRT parameters						
TO (%)	−0.01 ± 0.02	−0.012 ± 0.02	−0.010 ± 0.02	0.46	0.39	0.80
TS (ms)	7.39 ± 6.05	5.33 ± 6.57	7.77 ± 5.21	0.91	0.53	0.10

HRV: Heart rate variability, HRT: Heart rate turbulence, TO: Turbulence onset, TS: Turbulence slope.

(clopidogrel, ticagrelor) had no effect on the parameters of HRV. Previous studies showed that, the VLF values was changing with respiratory oscillation and oxygen-sensitive mechanism [24,25]. Giannoni et al., found that ticagrelor may lead to periodic breathing, with alternating apnea and hyperventilation [26]. In the light of these data, respiratory and VLF variation

in ticagrelor is expected. However there was no change in the VLF values of our patients. The absence of a significant change in the VLF values of our patients can be explained by the absence of a significant respiratory distress in our patients.

HRT is primarily a reflection of the vagal tone that antagonizes the sympathetic increase [16]. It is also

Table 5. Comparison of the HRV and HRT parameters in different treatment phase.

(n:30)				P 1 Value	P 2 Value	P 3 Value
Study Period	Clopidogrel (Baseline)	Clopidogrel (After PCI)	Ticagrelor (After PCI)			
Mean R–R time (ms)	894.60 ± 100.46	867.37 ± 118.74	876.71 ± 91.29	0.09	0.23	0.50
HRV (Frequency domain)						
TP (ms ²)	2738.80 ± 1883.54	3070.40 ± 2480.86	2991.33 ± 2504.59	0.94	0.24	0.42
VLF(ms ²)	2506.10 ± 2519.36	2436.30 ± 1898.31	2456.73 ± 1537.75	0.97	0.30	0.60
VLF (nu)	80.72 ± 5.38	79.74 ± 6.26	80.23 ± 5.53	0.44	0.32	0.86
LF (ms ²)	700.66 ± 734.71	730.40 ± 894.39	656.30 ± 580.98	0.78	0.19	0.83
LF (nu)	19.27 ± 5.38	20.25 ± 6.26	19.76 ± 5.52	0.44	0.32	0.84
HF(ms ²)	437.20 ± 441.54	432.96 ± 149.93	271.23 ± 41.76	0.62	0.96	0.18
HF (nu)	8.19 ± 8.39	9.08 ± 8.66	7.53 ± 6.46	0.47	0.64	0.17
LF/HF ratio	3.93 ± 2.43	3.48 ± 2.72	3.98 ± 2.57	0.21	0.49	0.12
HRV (Time domain)						
SDNN (ms)	104.18 ± 35.09	112.20 ± 30.10	113.57 ± 31.88	0.09	0.06	0.84
ASDNN (ms)	54.60 ± 23.81	52.95 ± 19.63	53.63 ± 15.95	0.64	0.62	0.50
rMSSD (ms)	38.87 ± 41.01	39.31 ± 29.58	35.43 ± 19.86	0.54	0.62	0.55
pNN50 (%)	7.69 ± 7.62	8.12 ± 8.07	6.68 ± 6.12	0.97	0.68	0.59
HRT parameters						
TO (%)	−0.0056 ± 0.02	−0.0058 ± 0.02	−0.0054 ± 0.02	0.78	0.23	0.18
TS (ms)	6.47 ± 5.68	6.85 ± 5.20	7.33 ± 7.06	0.59	0.28	0.90

HRV: Heart rate variability, HRT: Heart rate turbulence, TO: Turbulence onset, TS: Turbulence slope. P 1 value: Clopidogrel (baseline) vs Clopidogrel (after PCI), P 2 Value: Clopidogrel (baseline) vs Ticagrelor (after PCI), P 3 Value: Clopidogrel (after PCI) vs Ticagrelor (after PCI).

considered as a noninvasive indicator of spontaneous baroreceptor sensitivity [27]. The European Heart Association has stated that HRT is a good indicator of vagal activity and an independent predictor of total mortality [28]. In our study, the TO parameter of group 1 was positive at baseline and higher than group 2. This is consistent with the fact that parasympathetic autonomic functions of group 1 are weaker than group 2. Sympathetic activity in group 1 seems to be more dominant. However, the applied treatments (clopidogrel, ticagrelor) did not make any difference in terms of HRT parameters in the comparison between the two groups and in each group. That is, clopidogrel and ticagrelor did not have a significant effect on HRT parameters.

4.1. Limitations of the study

The present study only included a small number of patients, and only short-term records were obtained. Our study population left ventricular function was in normal value. HRV and HRT parameters can alter in low ventricular function population. Furthermore, there were no complications such as respiratory distress and arrhythmia in our study population. Also, respiratory distress may affect the HRV and HRT parameters. Another limitation is that the levels of adenosine, ticagrelor and platelet reactivity unit were not measured. However, our randomized crossover design study could overcome these limitations and may serve as a guide for larger-scale studies.

5. Conclusion

Clopidogrel and ticagrelor therapy in PCI patients have been shown to have no effect on cardiac autonomic functions assessed by the HRV and HRT parameters. This study will be a guide to studies in larger and different patient populations.

Statement of ethics

The study was performed after approval was obtained from the local Ethics Committee.

Funding

This research received no external funding.

Declaration of Competing Interest

The authors have no relevant conflicts of interest to disclose.

Acknowledgments

We want to thank our cardiology service nurses.

References

- [1] Bae JS, Jang JS. Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis. *Heart Ves* 2016;31(3): 275–87.
- [2] Furuse E, Takano H, Yamamoto T, Kubota Y, Yoshizane T, Kitamura M, et al. Time course of the antiplatelet effect after switching to clopidogrel from initial prasugrel therapy in

- patients with acute coronary syndrome. *Heart Ves* 2017; 32(12):1432–8.
- [3] Latkovskis G, Urtane I, Knipse A, Peculis R, Cakstina I, Klovinis J, et al. Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness. *Medicina (Kau-nas)*. 2014;50(1):19–27.
- [4] Zhuo ZL, Xian HP, Long Y, Liu C, Sun YY, Ma YT, et al. Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients. *Anatol J Cardiol* 2018;19(2):123–9.
- [5] Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. *J Am Coll Cardiol* 2014;63(9):872–7.
- [6] Cattaneo M, Schulz R, Nylander S. Adenosine-Mediated effects of ticagrelor evidence and potential clinical relevance. *J Am Coll Cardiol* 2014;63:2503–9.
- [7] Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009;361:1045–57.
- [8] Ortega-Paz L, Brugaletta S, Ariotti S, Akkerhuis KM, Karagiannis A, Windecker S, et al. Adenosine and ticagrelor plasma levels in patients with and without ticagrelor-related dyspnea. *Circulation* 2018;138:646–8.
- [9] Gourine AV, Kasymov V, Marina N, Tang F, Figueiredo MF, Lane S, et al. Astrocytes control breathing through pH-dependent release of ATP. *Science* 2010; 329(5991):571–5.
- [10] Biaggioni I. Adenosine receptors and autonomic regulation. In: Robertson D, Biaggioni I, Burnstock G, editors. *Primer on the autonomic nervous system*. 3rd ed. Elsevier; 2012. p. 95–7.
- [11] Kou WH, Man KC, Goyal R, Strickberger SA, Morady F. Interaction between autonomic tone and the negative chronotropic effect of adenosine in humans. *Pacing Clin Electrophysiol* 1999;22(12):1792–6.
- [12] Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. *Circ Res* 1986;59: 178–93.
- [13] Malik M, Bigger JT, Camm AJ, Kleiger RE, Malliani A, Moss AJ, et al. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Task force of the European society of cardiology and the north American society of pacing and electrophysiology. *Eur Heart J* 1996;17(3):354–81.
- [14] Kudaiberdieva G, Görennek B, Timuralp B. Heart rate variability as a predictor of sudden cardiac death. *Anatol J Cardiol* 2007;7(Suppl 1):68–70.
- [15] Schmidt G, Malik M, Barthel P, Schneider R, Ulm K, Rolnitzky L, et al. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. *Lancet* 1999;353:1390–6.
- [16] Watanabe MA, Schmidt G. Heart rate turbulence: a 5-year review. *Heart Rhythm* 2004;1:732–8.
- [17] Van Giezen JJ, Sidaway J, Glaves P, Kirk I, Björkman JA. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. *J Cardiovasc Pharmacol Therapeut* 2012;17:164–72.
- [18] Armstrong A, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. *J Cardiovasc Pharmacol Therapeut* 2014;19:209–19.
- [19] Headrick JP, Ashton KJ, Rose-meyer RB, Peart JN. Cardiovascular adenosine receptors: expression, actions and interactions. *Pharmacol Ther* 2013;140:92–111.
- [20] Mustafa SJ, Morrison RR, Teng B, Pelleg A. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. *Handb Exp Pharmacol* 2009;193:161–88.
- [21] Biaggioni I. Contrasting excitatory and inhibitory effects of adenosine in blood pressure regulation. *Hypertension* 1992; 20:457–65.
- [22] Göncü T, Tiryakioğlu O, Özcan A, Arö H, Sezen M, Vural H, et al. Inhibitory effects of ticlopidine and clopidogrel on the intimal hyperplastic response after arterial injury. *Anatol J Cardiol* 2010;10(1):11–6.
- [23] Berntson GG, Bigger Jr JT, Eckberg DL, Grossman P, Kaufmann PG, Malik M, et al. Heart rate variability: origin, methods, and interpretive caveats. *Psychophysiology* 1997; 34:623–48.
- [24] Francis DP, Davies LC, Willson K, Ponikowski P, Coats AJ, Piepoli M. Very-low-frequency oscillations in heart rate and blood pressure in periodic breathing: role of the cardiovascular limb of the hypoxic chemoreflex. *Clin Sci (Lond)*. 2000 Aug;99(2):125–32.
- [25] Szollosi I, Krum H, Kaye D, Naughton MT. Sleep apnea in heart failure increases heart rate variability and sympathetic dominance. *Sleep* 2007 Nov;30(11):1509–14.
- [26] Giannoni A, Emdin M, Passino C. Cheyne-Stokes respiration, chemoreflex, and ticagrelor-related dyspnea. *N Engl J Med* 2016 Sep 8;375(10):1004–6.
- [27] La Rovere MT, Maestri R, Pinna GD, Sleight P, Febo O. Clinical and haemodynamic correlates of heart rate turbulence as a non-invasive index of baroreflex sensitivity in chronic heart failure. *Clin Sci (Lond)* 2011;121(6):279–84.
- [28] Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, et al. Task force on sudden cardiac death of the European society of cardiology. *Eur Heart J* 2001; 22:1374–450.